Fig. 2: Antibody levels against SARS-CoV-2 nucleocapsid and spike protein in hematologic patients with COVID-19. | Blood Cancer Journal

Fig. 2: Antibody levels against SARS-CoV-2 nucleocapsid and spike protein in hematologic patients with COVID-19.

From: Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab

Fig. 2

Antibody levels against SARS-CoV-2 nucleocapsid (NAb) and spike protein (S-Ab) were determined among the follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLCL) compared with patients with other hematological malignancies. Each symbol represents an individual patient sample from 1 (M1), 3 (M3), and 6 (M6) months after nasal swabs became PCR-negative. Antibody levels are plotted in light units (LU) on the y axis and the solid horizontal line represents the mean level for each group. Statistically significant differences in antibody levels among the sample group were determined by a Student’s t test.

Back to article page